Skip Navigation LinksHome > September 2012 - Volume 24 - Issue 5 > Molecular targets and targeted therapeutics in endometrial c...
Current Opinion in Oncology:
doi: 10.1097/CCO.0b013e328354e585
GYNECOLOGIC CANCER: Edited by Martin Gore

Molecular targets and targeted therapeutics in endometrial cancer

Weigelt, Brittaa; Banerjee, Susanab

Collapse Box


Purpose of review: Endometrial cancer is the most common gynaecological malignancy in the western world. Two clinicopathological subtypes are recognized: type I (endometrioid) and type II (nonendometrioid) carcinomas. This review describes the molecular alterations in endometrial cancer and how this knowledge is leading to the development of novel treatments in this area.

Recent findings: Molecularly targeted agents have entered clinical trials in endometrial cancer. So far, mechanistic target of rapamycin (mTOR) inhibitors and antiangiogenic agents appear promising and are being pursued further in addition to other targeted approaches.

Summary: The clinicopathological and molecular heterogeneity of endometrial cancer needs to be taken into account in the design of future clinical trials as well as the incorporation of robust biomarkers for the success of therapeutic strategies in endometrial cancer.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.